The Briefing Room
General Category => Health/Education => Topic started by: PeteS in CA on October 07, 2020, 05:10:31 pm
-
Moderna sees shortcomings in coronavirus trial minority enrollment, faces delays: report
https://www.foxbusiness.com/lifestyle/moderna-sees-shortcomings-in-coronavirus-trial-minority-enrollment-faces-delays-report (https://www.foxbusiness.com/lifestyle/moderna-sees-shortcomings-in-coronavirus-trial-minority-enrollment-faces-delays-report)
Moderna’s hired contractors have not enrolled enough trial participants from minority groups to determine efficacy in these populations, per a report.
To address the shortcoming, the company reportedly slowed its late-stage trial enrollment and directed a focus on the inclusion of Black, Latino and Native American volunteers, executives told Reuters. Academic researchers who already have rapport in these communities are said to be assisting the effort.
...
Dr. Paul Evans, chief executive of Velocity Clinical Research in Durham, N.C., and hired to test the vaccine at five sites, reportedly said the task of minority enrollment for “proper population balance is ‘notoriously difficult’†across any trial.
It doesn't help wrt this specific group of vaccines that Calypso Louie and probably other race-baiting misleaders out there agitating against "white vaccines". AstraZeneca may have made wise moves in going early to South Africa and Brazil in their Phase III testing.